-transparent.png){kind=logo}
An 80-year-old man with advanced adenocarcinoma of the prostate received cyproterone acetate, 200 mg orally per day as sole treatment. Striking regression of the tumour was demonstrated by ultrasonograms and excretory urograms. Serum concentrations of acid phosphatases, gonadotrophins, and testosterone decreased significantly. No significant cardiovascular side effects occurred.
Related Publications
E Varenhorst, and
U Björnlert, and
K Carlström
January 1997,
International urology and nephrology,
E Varenhorst, and
U Björnlert, and
K Carlström
January 1995,
Urologiia i nefrologiia,
E Varenhorst, and
U Björnlert, and
K Carlström
August 1976,
British journal of urology,
E Varenhorst, and
U Björnlert, and
K Carlström
January 1978,
Scandinavian journal of urology and nephrology,
E Varenhorst, and
U Björnlert, and
K Carlström
April 1987,
Gastroenterologie clinique et biologique,
E Varenhorst, and
U Björnlert, and
K Carlström
January 1996,
Khirurgiia,
E Varenhorst, and
U Björnlert, and
K Carlström
January 1985,
Schweizer Archiv fur Neurologie und Psychiatrie (Zurich, Switzerland : 1985),
E Varenhorst, and
U Björnlert, and
K Carlström
January 2013,
Annals of hepatology,
E Varenhorst, and
U Björnlert, and
K Carlström
January 1991,
Schweizer Archiv fur Neurologie und Psychiatrie (Zurich, Switzerland : 1985),
E Varenhorst, and
U Björnlert, and
K Carlström
May 2014,
Canadian Urological Association journal = Journal de l'Association des urologues du Canada,
